MEDICAL ONCOLOGY SERVICES OVERVIEW
Krishna Cancer Hospital boasts a team of highly qualified, experienced, and dedicated medical oncologists. Our approach to treatment adheres to evidence-based, internationally approved chemotherapy guidelines for a wide range of solid and hematological malignancies.
In addition to active chemotherapy, our medical oncology department provides comprehensive palliative care to patients, ensuring optimal support beyond treatment limitations. Our outpatient department operates from Monday to Saturday, from 9:00 AM to 5:30 PM, with 24x7 emergency services.
Our medical oncology department is staffed with specially trained nurses and support personnel, facilitating chemotherapy administration in both day care and inpatient settings. Chemotherapy drugs are prepared in a dedicated Cytotoxic Admixture lab, ensuring stringent quality controls under laminar airflow conditions.
Targeted therapy is a type of cancer treatment that specifically targets certain molecules or pathways involved in the growth and survival of cancer cells. Unlike traditional chemotherapy, which can affect both cancerous and healthy cells, targeted therapy aims to interfere with specific proteins, genes, or other molecules that are more prevalent in cancer cells or play a critical role in cancer progression.
These therapies are often tailored to the individual's cancer based on genetic or molecular characteristics. Common types of targeted therapy include monoclonal antibodies, small molecule drugs, and immunotherapies. Targeted therapy can be used alone or in combination with other cancer treatments such as chemotherapy, radiation therapy, or surgery.
Hormone therapy has limited use in cancer treatment since only minority of tumours are hormone sensitive e.g. breast and prostate cancer. This therapy provides systemic means of treatment to the whole body, but without the side effects of chemotherapy.
Immunotherapy is a form of treatment which stimulates the body’s immune system to destroy cancer cells. But it is expensive.